Business Information
The group's principal activity are to discover, develop and commercialize antibody, protein and peptide based therapeutic products for unmet medical conditions, particularly in the areas of inflammation and oncology. The two product candidates in clinical trials are dx-88 and dx-890. The group has collaborative agreements for the development of both of these product candidates. Dx-88 is in phase ii trials for the potential treatment of hereditary angioedema in collaboration with genzyme corporation. The group's second clinical compound, dx-890, is in phase ii clinical trials for the potential treatment of cystic fibrosis. The group uses its proprietary, patented technology, known as phage display, to identify human monoclonal antibodies, small proteins and peptides as potential therapeutics for the treatment of various conditions and diseases. On 29-Oct-2003, the group discontinued its operations of biotage llc.
|
|
Name |
Title
|
Email
|
| Henry Blair | Chmn., CEO, Pres. | N/A | | Clive Wood | Exec. VP - Discovery Research, Chief Scientific Officer | N/A | | Gustav Christensen | Exec. VP, Chief Business Officer | N/A | | Ivana Magovcevic-Liebisch | General Counsel, Exec. VP - Administration | N/A | | Stephen Galliker | Exec. VP - Finance, Administration, CFO | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 12,776 | (50,323) | | 2005 | 19,859 | (30,944) | | 2004 | 16,590 | (33,114)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
